Emergent BioSolutions (EBS) Tops Q1 EPS by 23c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/4/2026
- Wall St set for higher open as Democrats win Congress; data center stocks slide
- What the Democratic sweep in the midterms means for markets
- SpaceX, Tesla slide as election risks mount, Morgan Stanley turns bullish
- CVS Health plans to split into two public companies by 2028
- AI sector outlook darkens as Democrat wins threaten $900B capex cycle
Tweet
Share
E-mailGet Alerts EBS Hot Sheet
Price: $6.25 --0%
Financial Fact:
Net income (loss) attributable to Emergent BioSolutions Inc.: 21.34M
Today's EPS Names:
ATS, SICP, FTCO, More
Financial Fact:
Net income (loss) attributable to Emergent BioSolutions Inc.: 21.34M
Today's EPS Names:
ATS, SICP, FTCO, More
Join SI Premium – FREE
Emergent BioSolutions (NYSE: EBS) reported Q1 EPS of $0.16, $0.23 better than the analyst estimate of ($0.07). Revenue for the quarter came in at $111 million versus the consensus estimate of $101.83 million.
For earnings history and earnings-related data on Emergent BioSolutions (EBS) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Southwest Gas (SWX) Tops Q3 EPS by 2c; Offers Guidance
- XPEL, Inc. (XPEL) Tops Q3 EPS by 4c, Misses on Revenue; Offers Q4 Revenue Guidance
- Harmony Biosciences (HRMY) Misses Q3 EPS by 30c; Offers Guidance
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
